4519 中外薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2025/12	3Q	911,640	429,827	47.1%	-	-	305,602	33.5%	185.70	5.0%	2.7%	0.0%	3.3%
2024/12	3Q	868,538	418,602	48.2%	-	-	295,758	34.1%	179.75	3.7%	31.8%	0.0%	26.2%
2023/12	3Q	837,555	317,598	37.9%	-	-	234,266	28.0%	142.40	2.0%	-17.3%	0.0%	-13.9%
2022/12	3Q	821,450	383,835	46.7%	-	-	271,950	33.1%	165.35	21.2%	35.7%	0.0%	33.2%
2021/12	3Q	677,493	282,835	41.7%	-	-	204,154	30.1%	124.17	17.5%	24.4%	0.0%	25.7%
2020/12	3Q	576,520	227,318	39.4%	-	-	162,425	28.2%	98.84	13.3%	41.3%	0.0%	38.4%
2019/12	3Q	508,851	160,878	31.6%	-	-	117,395	23.1%	214.48	19.3%	64.3%	0.0%	66.9%
2018/12	3Q	426,440	97,912	23.0%	-	-	70,340	16.5%	128.60	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2025/12	3Q	43,102	11,225	26.0%	-	-	9,844	22.8%	5.95	39.1%	-88.9%	0.0%	-84.0%
2024/12	3Q	30,983	101,004	326.0%	-	-	61,492	198.5%	37.35	92.4%	黒転	0.0%	黒転
2023/12	3Q	16,105	-66,237	-411.3%	-	-	-37,684	-234.0%	-22.95	-88.8%	赤転	0.0%	赤転
2022/12	3Q	143,957	101,000	70.2%	-	-	67,796	47.1%	41.18	42.6%	81.9%	0.0%	62.5%
2021/12	3Q	100,973	55,517	55.0%	-	-	41,729	41.3%	25.33	49.2%	-16.4%	0.0%	-7.3%
2020/12	3Q	67,669	66,440	98.2%	-	-	45,030	66.5%	-115.64	-17.9%	5.5%	0.0%	-4.3%
2019/12	3Q	82,411	62,966	76.4%	-	-	47,055	57.1%	85.88	-80.7%	-35.7%	0.0%	-33.1%
2018/12	3Q	426,440	97,912	23.0%	-	-	70,340	16.5%	128.60	-	-	-	-